- ►diabetesjournals.org K Hällsten, KA Virtanen, F Lönnqvist, H … - Diabetes, 2002 - Am Diabetes Assoc Rosiglitazone, a thiazolidinedione, enhances peripheral insulin sensitivity in
patients with type 2 diabetes. Because the synergic action of insulin and
exercise has been shown to be decreased in insulin resistance, the aim of ... Cited by 97 - Related articles - BL Direct - All 6 versions
KA Virtanen, K Hällsten, R Parkkola, T … - Diabetes, 2003 - Am Diabetes Assoc We evaluated the effects of rosiglitazone (4 mg bid) and metformin (1 g bid)
monotherapy for 26 weeks on adipose tissue insulin-stimulated glucose uptake in
patients (n = 41) with type 2 diabetes. Before and after the treatment, ... Cited by 111 - Related articles - BL Direct - All 4 versions
- Free from Publisher P Iozzo, K Hallsten, V Oikonen, KA Virtanen, R … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Fasting plasma glucose levels were significantly decreased after
either rosiglitazone (−0.9 ± 0.5 mmol/l) or metformin treatment (−1.1 ±
0.5 mmol/l) in comparison with placebo; only metformin was associated with ... Cited by 36 - Related articles - BL Direct - All 5 versions
- ►endojournals.org I Pavo, G Jermendy, TT Varkonyi, Z Kerenyi, … - Journal of Clinical Endocrinology & Metabolism, 2003 - Endocrine Soc Pioglitazone, a thiazolidinedione, improves glycemic control primarily by
increasing peripheral insulin sensitivity in patients with type 2 diabetes,
whereas metformin, a biguanide, exerts its effect primarily by decreasing ... Cited by 104 - Related articles - BL Direct - All 5 versions
FJ Gómez-Perez, G Fanghänel-Salmón, JA … - Diabetes/Metabolism Reviews - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 90 - Related articles - BL Direct - All 4 versions
S Nagasaka, Y Aiso, K Yoshizawa, S … - Diabetic medicine, 2004 - interscience.wiley.com Methods Seventy-eight Japanese subjects with Type 2 diabetes mellitus poorly
controlled with sulphonylureas [38 men and 40 women, aged 57 ± 9 years, body
mass index 25.2 ± 1.4 kg/m 2 , and HbA 1c 8.3 ± 0.6% (means ± sd)] were ... Cited by 27 - Related articles - BL Direct - All 4 versions
K Hallsten, KA Virtanen, F Lonnqvist, T … - Diabetic Medicine, 2004 - pt.wkhealth.com Aims: Peroxisome proliferator-activated receptor γ (PPARγ) activators have
recently been identified as regulators of cellular proliferation, inflammatory
responses and lipid and glucose metabolism. These agents prevent coronary ... Cited by 42 - Related articles - BL Direct - All 6 versions
TP Ciaraldi, APS Kong, NV Chu, DD Kim, S … - Diabetes, 2002 - Am Diabetes Assoc Type 2 diabetic subjects failing glyburide therapy were randomized to receive
additional therapy with either metformin (2,550 mg/day) or troglitazone (600
mg/day) for 3–4 months. Biopsies of subcutaneous abdominal adipose tissue ... Cited by 67 - Related articles - BL Direct - All 4 versions
Y Miyazaki, L Glass, C Triplitt, M Matsuda, … - Diabetologia, 2001 - Springer The thiazolidinediones represent a new class of insu- lin sensitizing agents for
the treatment of Type II (non-insulin-dependent) diabetes mellitus. The origi-
nal drug in this class, troglitazone, has been shown to ameliorate insulin ... Cited by 205 - Related articles - BL Direct - All 5 versions
TA Jones, M Sautter, LF Van Gaal, NP Jones - Diabetes Obesity and Metabolism, 2003 - interscience.wiley.com Aim: These analyses were undertaken to evaluate the efficacy of the insulin
sensitizer rosiglitazone (RSG) when added to the therapy of obese type 2
diabetes mellitus patients (T2DM) taking near-maximal doses (2.5 g/day) of ... Cited by 82 - Related articles - BL Direct - All 3 versions
